
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7238976/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 111-121.	0.7	6
2	Ephrin Ligands are Upregulated in the Saliva of SARSâ€CoVâ€2 Infected Patients. FASEB Journal, 2022, 36, .	0.5	1
3	The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Plays an Important Role in Fetal Human Colon Cell Migration and Proliferation. FASEB Journal, 2022, 36, .	0.5	0
4	The Uncertain Role of Corticosteroids in the Treatment of COVID-19. JAMA Internal Medicine, 2021, 181, 139.	5.1	3
5	Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
6	SARSâ€CoVâ€2 innate effector associations and viral load in early nasopharyngeal infection. Physiological Reports, 2021, 9, e14761.	1.7	15
7	Hypoxia induces expression of angiotensinâ€converting enzyme II in alveolar epithelial cells: Implications for the pathogenesis of acute lung injury in COVIDâ€19. Physiological Reports, 2021, 9, e14854.	1.7	9
8	Enhanced epithelial sodium channel activity in neonatal Scnn1b mouse lung attenuates high oxygen-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L29-L41.	2.9	4
9	Spotlighting "Neutrophil Elastase Triggers the Release of Macrophage Extracellular Traps†A New Catch in CF?. American Journal of Respiratory Cell and Molecular Biology, 2021, , .	2.9	0
10	High-mobility group box-1 increases epithelial sodium channel activity and inflammation via the receptor for advanced glycation end products. American Journal of Physiology - Cell Physiology, 2020, 318, C570-C580.	4.6	2
11	Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. Scientific Reports, 2020, 10, 6602.	3.3	11
12	Impact of low-level fine particulate matter and ozone exposure on absences in K-12 students and economic consequences. Environmental Research Letters, 2020, 15, 114052.	5.2	16
13	Role of cystic fibrosis transmembrane conductance regulator in FHC colon epithelial cell dysfunction and colon cancer. FASEB Journal, 2020, 34, 1-1.	0.5	0
14	Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88.	3.1	8
15	Modeling long-term health outcomes of patients with cystic fibrosis homozygous for <i>F508del-CFTR</i> treated with lumacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661882018.	2.6	23
16	Refinement of metabolite detection in cystic fibrosis sputum reveals heme correlates with lung function decline. PLoS ONE, 2019, 14, e0226578.	2.5	15
17	A multi-scale approach to study biochemical and biophysical aspects of resveratrol on diesel exhaust particle-human primary lung cell interaction. Scientific Reports, 2019, 9, 18178.	3.3	12
18	Longer Life or More Life: Choose One Please. Journal of Surgical Research, 2019, 237, 126-128.	1.6	0

#	Article	IF	CITATIONS
19	The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein. Chest, 2019, 155, 605-616.	0.8	34
20	RV/LV ratio in severe sepsis and septic shock: Response to Letter to the Editor. Journal of Critical Care, 2019, 50, 311-312.	2.2	2
21	Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology, 2018, 154, 736-745.e14.	1.3	131
22	Right-to-left ventricular end diastolic diameter ratio in severe sepsis and septic shock. Journal of Critical Care, 2018, 48, 307-310.	2.2	13
23	Microbial Interactions in the Cystic Fibrosis Airway. Journal of Clinical Microbiology, 2018, 56, .	3.9	45
24	Thailandamide, a Fatty Acid Synthesis Antibiotic That Is Coexpressed with a Resistant Target Gene. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
25	Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15
26	Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Chest, 2018, 154, 1108-1114.	0.8	17
27	Sleep Phase Delay in Cystic Fibrosis. Chest, 2017, 152, 386-393.	0.8	21
28	The Dynamics of Disease Progression in Cystic Fibrosis. PLoS ONE, 2016, 11, e0156752.	2.5	19
29	Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium. BMJ Open Diabetes Research and Care, 2016, 4, e000183.	2.8	7
30	Adolescents with cystic fibrosis: Take the door, not the window. Pediatric Transplantation, 2015, 19, 133-135.	1.0	0
31	Rib plating of acute and sub-acute non-union rib fractures in an adult with cystic fibrosis: a case report. BMC Research Notes, 2014, 7, 681.	1.4	9
32	Genetic Discovery, Rigorous Statistics, and Pandemic Influenza. Chest, 2014, 145, 1186-1188.	0.8	0
33	Use of older donors for lung transplantation—you can't get there from here. Journal of Heart and Lung Transplantation, 2013, 32, 757-759.	0.6	2
34	Lung transplantation for chronic obstructive pulmonary disease. Transplant Research and Risk Management, 2013, , 1.	0.7	2
35	Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. Chest, 2012, 142, 718-724.	0.8	290
36	Toxicity effects of short term diesel exhaust particles exposure to human small airway epithelial cells (SAECs) and human lung carcinoma epithelial cells (A549). Toxicology Letters, 2012, 215, 181-192.	0.8	22

#	Article	IF	CITATIONS
37	Sputum Biomarkers and the Prediction of Clinical Outcomes in Patients with Cystic Fibrosis. PLoS ONE, 2012, 7, e42748.	2.5	57
38	222 Right Heart Catheterization in Patients with Pulmonary Arterial Hypertension: Practice Patterns Observed in the REVEAL Registry. Journal of Heart and Lung Transplantation, 2011, 30, S80.	0.6	0
39	The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States. Chest, 2011, 139, 128-137.	0.8	303
40	Delay in Recognition of Pulmonary Arterial Hypertension. Chest, 2011, 140, 19-26.	0.8	228
41	Pulmonary Vascular Resistance in Systemic Sclerosis Patients With Pulmonary Hypertension. Chest, 2011, 140, 717A.	0.8	0
42	Four-Year Outcomes of Patients With Pulmonary Arterial Hypertension: Risk, Prognosis, and the Disease Duration Continuum. Chest, 2011, 140, 724A.	0.8	1
43	Modulating Pseudomonas aeruginosa chronic Inflammation With The Anti-PcrV Antibody KB001: Results Of A Pilot Clinical and Pharmacodynamic Study In Subjects With Cystic Fibrosis. , 2010, , .		1
44	Predicting Survival in Pulmonary Arterial Hypertension. Circulation, 2010, 122, 164-172.	1.6	1,353
45	Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterology Research and Practice, 2010, 2010, 1-7.	1.5	10
46	Pulmonary Arterial Hypertension. Chest, 2010, 137, 376-387.	0.8	1,018
47	Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 250-256.	0.7	98
48	Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia. Diabetes Care, 2009, 32, 1783-1788.	8.6	206
49	Lung Transplantation for Cystic Fibrosis. Proceedings of the American Thoracic Society, 2009, 6, 619-633.	3.5	65
50	Carrier Screening, Incidence of Cystic Fibrosis, and Difficult Decisions. JAMA - Journal of the American Medical Association, 2009, 302, 2595.	7.4	6
51	Measurement of Lung Volumes. Clinical Reviews in Allergy and Immunology, 2009, 37, 153-158.	6.5	2
52	Spirometry. Clinical Reviews in Allergy and Immunology, 2009, 37, 137-152.	6.5	32
53	622: Doxycycline Improves Decline in Pulmonary Function in OB/BOS. Journal of Heart and Lung Transplantation, 2009, 28, S281-S282.	0.6	0
54	A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and <i>Pseudomonas aeruginosa</i> infection. Pediatric Pulmonology, 2008, 43, 47-58.	2.0	96

#	Article	IF	CITATIONS
55	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. Mayo Clinic Proceedings, 2008, 83, 923-931.	3.0	74
56	Outcomes of Care by Hospitalists. New England Journal of Medicine, 2008, 358, 1755-1758.	27.0	0
57	Correction: Lung Transplantation and Survival in Children with Cystic Fibrosis. New England Journal of Medicine, 2008, 359, 536-536.	27.0	16
58	Lung Transplantation and Survival in Children with Cystic Fibrosis. New England Journal of Medicine, 2008, 359, e6.	27.0	4
59	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. Mayo Clinic Proceedings, 2008, 83, 923-931.	3.0	116
60	A COMPARISON OF REVEAL REGISTRY DEMOGRAPHIC DATA WITH OTHER/PRIOR REGISTRIES OF PULMONARY ARTERIAL HYPERTENSION (PAH). Chest, 2008, 134, 134P.	0.8	1
61	Pediatric Lung Transplantation for Cystic Fibrosis. Transplantation, 2008, 86, 636-637.	1.0	7
62	Lung Transplantation and Survival in Children with Cystic Fibrosis. New England Journal of Medicine, 2007, 357, 2143-2152.	27.0	186
63	REVEAL REGISTRY: MEDICAL HISTORY AND TIME TO DIAGNOSIS OF ENROLLED PATIENTS. Chest, 2007, 132, 631A.	0.8	6
64	REVEAL REGISTRY: TREATMENT HISTORY AND TREATMENT AT BASELINE. Chest, 2007, 132, 631A.	0.8	9
65	Lung transplantation for cystic fibrosis. Current Opinion in Pulmonary Medicine, 2006, 12, 459-463.	2.6	21
66	LUNG TRANSPLANTATION OF CHILDREN WITH CYSTIC FIBROSIS FAILS TO IMPROVE SURVIVAL. Chest, 2006, 130, 138S.	0.8	0
67	Testing Lung Function Decline to Time Lung Transplantation. Chest, 2005, 128, 472-473.	0.8	6
68	BIVENTRICULAR FAILURE POST TAMPONADE DRAINAGE IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND PULMONARY HYPERTENSION. Chest, 2005, 128, 461S.	0.8	2
69	Use of Lung Transplantation Survival Models to Refine Patient Selection in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1053-1059.	5.6	127
70	Epidemiology of cystic fibrosis-related diabetes. Journal of Pediatrics, 2005, 146, 681-687.	1.8	279
71	Increasing pneumococcal vaccination rates among adults with cystic fibrosis. American Journal of Health-System Pharmacy, 2004, 61, 1490-1493.	1.0	1
72	Value of Ophthalmologic Examination in Diagnosing Temporal Arteritis. JAMA - Journal of the American Medical Association, 2002, 287, 1528.	7.4	10

THEODORE G LIOU

#	Article	IF	CITATIONS
73	Influenza Vaccination Coverage Level at a Cystic Fibrosis Center. Pediatrics, 2002, 109, e80-e80.	2.1	38
74	Selection of patients with cystic fibrosis for lung transplantation. Current Opinion in Pulmonary Medicine, 2002, 8, 535-541.	2.6	11
75	Thick mucus hypothesis in cystic fibrosis. Lancet, The, 2001, 357, 1204.	13.7	0
76	Survival Effect of Lung Transplantation Among Patients With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2001, 286, 2683.	7.4	156
77	Predictive 5-Year Survivorship Model of Cystic Fibrosis. American Journal of Epidemiology, 2001, 153, 345-352.	3.4	647
78	Elusiveness of ideal approach to Pseudomona aeruginosa infection complicating cystic fibrosis. Lancet, The, 2000, 356, 613-614.	13.7	7
79	Inhaled Nitric Oxide Versus Conventional Therapy. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1372-1380.	5.6	267
80	Nonisotropic Enzyme-Inhibitor Interactions: A Novel Nonoxidative Mechanism for Quantum Proteolysis by Human Neutrophils. Biochemistry, 1995, 34, 16171-16177.	2.5	94